JBT Marel

Alternative Proteins And Integration Setbacks Will Squeeze Margins

AnalystLowTarget

Not Invested

Community Contributor

Published

11 Jul 25

AnalystLowTarget's Fair Value

US$88.23

66.4% overvalued

03 Sep

US$146.82

47.0%

7.0%

47.0%

7.0%

You can edit this narrative until Jul 11 10:20 PM. Then, changes will post as Updates.

Author's Valuation

US$88.2366.4% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$88.23

66.4% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.07%

Machinery revenue growth rate

0.33%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.68%

Calculation

US$517.11m

Earnings '28

13.75x

PE Ratio '28

US$7.11b

Market Cap '28

US$7.11b

Market Cap '28

63.67m

No. shares '28

US$111.72

Share Price '28

US$111.72 Share Price '28

Discounted to 2025 @ 8.56% p.a.

US$87.31

Fair Value '25